Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Showroomprive.com: Showroomprivé launches its capital increase with preferential subscription rights of around €10 million
Showroomprive.com: Showroomprivé launches its capital increase with preferential subscription rights of around €10 million
Showroomprive.com: Showroomprivé launches its capital increase with preferential subscription rights of around €10 million
Voltalia SA: Total number of shares and voting rights in the share capital as of June 30, 2020
Voltalia SA: Total number of shares and voting rights in the share capital as of June 30, 2020
Voltalia SA: Total number of shares and voting rights in the share capital as of June 30, 2020
Kaufman & Broad SA: H1 2020 RESULTS
Kaufman & Broad SA: H1 2020 RESULTS
Kaufman & Broad SA: H1 2020 RESULTS
Voltalia SA: half-year statement of the liquidity contract, as of June 30, 2020
Voltalia SA: half-year statement of the liquidity contract, as of June 30, 2020
Voltalia SA: half-year statement of the liquidity contract, as of June 30, 2020
RUBIS: Half-year statement on Rubis' liquidity contract with Exane BNP Paribas
RUBIS: Half-year statement on Rubis' liquidity contract with Exane BNP Paribas
RUBIS: Half-year statement on Rubis' liquidity contract with Exane BNP Paribas
Voltalia SA: IKEA France and Voltalia sign a partnership to provide households with turnkey solar panel solutions
Voltalia SA: IKEA France and Voltalia sign a partnership to provide households with turnkey solar panel solutions
Voltalia SA: IKEA France and Voltalia sign a partnership to provide households with turnkey solar panel solutions
Kaufman & Broad SA: Half-year Liquidity contract
Kaufman & Broad SA: Half-year Liquidity contract
Kaufman & Broad SA: Half-year Liquidity contract
Sartorius Stedim Biotech SA: Half-year report of the liquidity contract with the stockbroker company Gilbert Dupont
Sartorius Stedim Biotech SA: Half-year report of the liquidity contract with the stockbroker company Gilbert Dupont
Sartorius Stedim Biotech SA: Half-year report of the liquidity contract with the stockbroker company Gilbert Dupont
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
DGAP-News: Abivax behandelt ersten Patienten in der klinischen Phase 2b/3-Covid-19-Studie mit ABX464
DGAP-News: Abivax behandelt ersten Patienten in der klinischen Phase 2b/3-Covid-19-Studie mit ABX464
DGAP-News: Abivax behandelt ersten Patienten in der klinischen Phase 2b/3-Covid-19-Studie mit ABX464
DGAP-News: Abivax treats first patient in Phase 2b/3 ABX464 Covid-19 clinical trial
DGAP-News: Abivax treats first patient in Phase 2b/3 ABX464 Covid-19 clinical trial
DGAP-News: Abivax treats first patient in Phase 2b/3 ABX464 Covid-19 clinical trial
DGAP-News: Abivax provides business update on most recent achievements and announces positive results of annual ordinary and extraordinary general meeting
DGAP-News: Abivax provides business update on most recent achievements and announces positive results of annual ordinary and extraordinary general meeting
DGAP-News: Abivax provides business update on most recent achievements and announces positive results of annual ordinary and extraordinary general meeting
DGAP-News: Abivax gibt Update zu jüngsten Unternehmenserfolgen und verkündet positive Ergebnisse seiner ordentlichen und außerordentlichen Jahreshauptversammlung
DGAP-News: Abivax gibt Update zu jüngsten Unternehmenserfolgen und verkündet positive Ergebnisse seiner ordentlichen und außerordentlichen Jahreshauptversammlung
DGAP-News: Abivax gibt Update zu jüngsten Unternehmenserfolgen und verkündet positive Ergebnisse seiner ordentlichen und außerordentlichen Jahreshauptversammlung
Edison Investment Research Limited: Edison issues outlook on Riber (RIB)
Edison Investment Research Limited: Edison issues outlook on Riber (RIB)
Edison Investment Research Limited: Edison issues outlook on Riber (RIB)
DGAP-News: ABIVAX: Abivax receives € 5m non-dilutive financing from Société Générale as State Guaranteed Loan
DGAP-News: ABIVAX: Abivax receives € 5m non-dilutive financing from Société Générale as State Guaranteed Loan
DGAP-News: ABIVAX: Abivax receives € 5m non-dilutive financing from Société Générale as State Guaranteed Loan
DGAP-News: Abivax erhält nicht-verwässernde Finanzierung  in Höhe von EUR 5 Mio. als staatlich gesichertes Darlehen von Société Générale
DGAP-News: Abivax erhält nicht-verwässernde Finanzierung  in Höhe von EUR 5 Mio. als staatlich gesichertes Darlehen von Société Générale
DGAP-News: Abivax erhält nicht-verwässernde Finanzierung  in Höhe von EUR 5 Mio. als staatlich gesichertes Darlehen von Société Générale
GEVELOT S.A.: AGM 2020 Press release
GEVELOT S.A.: AGM 2020 Press release
GEVELOT S.A.: AGM 2020 Press release
RUBIS: Option for the payment of the 2019 dividend in shares
RUBIS: Option for the payment of the 2019 dividend in shares
RUBIS: Option for the payment of the 2019 dividend in shares
Pharnext announces its 2020 Annual General Meeting to be held on July 17, 2020
Pharnext announces its 2020 Annual General Meeting to be held on July 17, 2020
Pharnext announces its 2020 Annual General Meeting to be held on July 17, 2020
Voltalia SA: total number of shares and voting rights in the share capital as of May 31, 2020
Voltalia SA: total number of shares and voting rights in the share capital as of May 31, 2020
Voltalia SA: total number of shares and voting rights in the share capital as of May 31, 2020
Pharnext provides regulatory and clinical update  on PXT3003 Phase III study  for the treatment of Charcot-Marie-Tooth Type 1A
Pharnext provides regulatory and clinical update on PXT3003 Phase III study for the treatment of Charcot-Marie-Tooth Type 1A
Pharnext provides regulatory and clinical update on PXT3003 Phase III study for the treatment of Charcot-Marie-Tooth Type 1A
Voltalia SA: Total number of shares and voting rights in the share capital as of April 30, 2020
Voltalia SA: Total number of shares and voting rights in the share capital as of April 30, 2020
Voltalia SA: Total number of shares and voting rights in the share capital as of April 30, 2020
Voltalia SA: Auchan Retail continues to reduce its carbon footprint and chooses Voltalia to source green electricity
Voltalia SA: Auchan Retail continues to reduce its carbon footprint and chooses Voltalia to source green electricity
Voltalia SA: Auchan Retail continues to reduce its carbon footprint and chooses Voltalia to source green electricity
Showroomprive.com: Adoption of resolutions allowing the implementation of the €8-10m capital increase project with maintaining the preferential subscription right underwritten by founding directors
Showroomprive.com: Adoption of resolutions allowing the implementation of the €8-10m capital increase project with maintaining the preferential subscription right underwritten by founding directors
Showroomprive.com: Adoption of resolutions allowing the implementation of the €8-10m capital increase project with maintaining the preferential subscription right underwritten by founding directors
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL